Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response

Paul J. Davis, Gennadi V. Glinsky, Hung Yun Lin, Sandra Incerpi, Faith B. Davis, Shaker A. Mousa, Heng Yuan Tang, Aleck Hercbergs, Mary K. Luidens

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. Tetraiodothyroacetic acid (tetrac) and its nanoparticulate formulation (Nanotetrac) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. Objective. The complex anti-angiogenic properties of tetrac and Nanotetrac caused us to search in the literature and in certain of our unpublished mRNA experiments for evidence that these agents affect the early inflammatory response, perhaps through actions on specific cytokines and chemokines. Results and Discussion. Tetrac and Nanotetrac inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that have been identified as high priority targets in the development of inflammation-suppressant drugs. The possibility is also examined that tetrac formulations have an effect on the function of inflammatory cells.

Original languageEnglish
Pages (from-to)112-118
Number of pages7
JournalEndocrine Research
Volume38
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

Thyroid Hormones
Chemokines
Cytokines
Genes
Chemokine Receptors
Interleukins
Cell Surface Receptors
Neoplasms
Cell Proliferation
Inflammation
Messenger RNA
tetraiodothyroacetic acid
Pharmaceutical Preparations

Keywords

  • Chemokines
  • Cytokines
  • Inflammation
  • Tetrac

ASJC Scopus subject areas

  • Endocrinology
  • Medicine(all)

Cite this

Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. / Davis, Paul J.; Glinsky, Gennadi V.; Lin, Hung Yun; Incerpi, Sandra; Davis, Faith B.; Mousa, Shaker A.; Tang, Heng Yuan; Hercbergs, Aleck; Luidens, Mary K.

In: Endocrine Research, Vol. 38, No. 2, 2013, p. 112-118.

Research output: Contribution to journalArticle

Davis, PJ, Glinsky, GV, Lin, HY, Incerpi, S, Davis, FB, Mousa, SA, Tang, HY, Hercbergs, A & Luidens, MK 2013, 'Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response', Endocrine Research, vol. 38, no. 2, pp. 112-118. https://doi.org/10.3109/07435800.2013.778865
Davis, Paul J. ; Glinsky, Gennadi V. ; Lin, Hung Yun ; Incerpi, Sandra ; Davis, Faith B. ; Mousa, Shaker A. ; Tang, Heng Yuan ; Hercbergs, Aleck ; Luidens, Mary K. / Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. In: Endocrine Research. 2013 ; Vol. 38, No. 2. pp. 112-118.
@article{7ccc6a8d98b94b4881ca95f5fd1a73ec,
title = "Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response",
abstract = "Background. Tetraiodothyroacetic acid (tetrac) and its nanoparticulate formulation (Nanotetrac) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. Objective. The complex anti-angiogenic properties of tetrac and Nanotetrac caused us to search in the literature and in certain of our unpublished mRNA experiments for evidence that these agents affect the early inflammatory response, perhaps through actions on specific cytokines and chemokines. Results and Discussion. Tetrac and Nanotetrac inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that have been identified as high priority targets in the development of inflammation-suppressant drugs. The possibility is also examined that tetrac formulations have an effect on the function of inflammatory cells.",
keywords = "Chemokines, Cytokines, Inflammation, Tetrac",
author = "Davis, {Paul J.} and Glinsky, {Gennadi V.} and Lin, {Hung Yun} and Sandra Incerpi and Davis, {Faith B.} and Mousa, {Shaker A.} and Tang, {Heng Yuan} and Aleck Hercbergs and Luidens, {Mary K.}",
year = "2013",
doi = "10.3109/07435800.2013.778865",
language = "English",
volume = "38",
pages = "112--118",
journal = "Endocrine Research",
issn = "0743-5800",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response

AU - Davis, Paul J.

AU - Glinsky, Gennadi V.

AU - Lin, Hung Yun

AU - Incerpi, Sandra

AU - Davis, Faith B.

AU - Mousa, Shaker A.

AU - Tang, Heng Yuan

AU - Hercbergs, Aleck

AU - Luidens, Mary K.

PY - 2013

Y1 - 2013

N2 - Background. Tetraiodothyroacetic acid (tetrac) and its nanoparticulate formulation (Nanotetrac) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. Objective. The complex anti-angiogenic properties of tetrac and Nanotetrac caused us to search in the literature and in certain of our unpublished mRNA experiments for evidence that these agents affect the early inflammatory response, perhaps through actions on specific cytokines and chemokines. Results and Discussion. Tetrac and Nanotetrac inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that have been identified as high priority targets in the development of inflammation-suppressant drugs. The possibility is also examined that tetrac formulations have an effect on the function of inflammatory cells.

AB - Background. Tetraiodothyroacetic acid (tetrac) and its nanoparticulate formulation (Nanotetrac) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. Objective. The complex anti-angiogenic properties of tetrac and Nanotetrac caused us to search in the literature and in certain of our unpublished mRNA experiments for evidence that these agents affect the early inflammatory response, perhaps through actions on specific cytokines and chemokines. Results and Discussion. Tetrac and Nanotetrac inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that have been identified as high priority targets in the development of inflammation-suppressant drugs. The possibility is also examined that tetrac formulations have an effect on the function of inflammatory cells.

KW - Chemokines

KW - Cytokines

KW - Inflammation

KW - Tetrac

UR - http://www.scopus.com/inward/record.url?scp=84875871009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875871009&partnerID=8YFLogxK

U2 - 10.3109/07435800.2013.778865

DO - 10.3109/07435800.2013.778865

M3 - Article

VL - 38

SP - 112

EP - 118

JO - Endocrine Research

JF - Endocrine Research

SN - 0743-5800

IS - 2

ER -